FDA begins process to remove breast cancer indication from Avastin label
The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.
Dec 16, 2010
Latest in Operations
Sonair Accelerating Rollout of 3D Ultrasonic Sensor for Robots
September 17, 2025